Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 3/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12138497 | 0.91 | GAA (0.36) | CYP3A4GAAAKR1C3ALDH1A1MAPT | |
| SCHEMBL1358340 | 0.90 | GAA (0.38) | CYP3A4GAAAKR1C3MAPTKDM4E | |
| SCHEMBL1359899 | 0.89 | CYP3A4 (0.33) | CYP3A4GAA | |
| SCHEMBL1360029 | 0.89 | ALDH1A1 (0.36) | CYP3A4GAAALDH1A1KDM4EMEN1 | |
| SCHEMBL1359241 | 0.89 | ALDH1A1 (0.36) | CYP3A4GAAALDH1A1KDM4EMEN1 | |
| SCHEMBL1358409 | 0.89 | ALDH1A1 (0.36) | CYP3A4GAAALDH1A1KDM4EMEN1 | |
| SCHEMBL1359987 | 0.89 | CHEK1 (0.36) | CYP3A4GAAAKR1C3ALDH1A1MAPT | |
| SCHEMBL1359797 | 0.85 | CHEK1 (0.38) | CYP3A4GAARAB9A | |
| SCHEMBL1359903 | 0.85 | CYP3A4 (0.37) | CYP3A4GAAKMT2A | |
| SCHEMBL1358332 | 0.85 | CYP3A4 (0.37) | CYP3A4GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067442-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067442-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2011-11-29 | — | — | US | disclosed |
| US-20100081658-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC | 2010-04-01 | — | — | US | disclosed |
| US-20100081658-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081658-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, POLR2A, HCCS | CYP3A4 713/4885GAA 2017/4885AKR1C3 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.